Analytical Data
-
基因名
KLK2
- Application
-
别名
KLK2；Kallikrein-2
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P20151
-
表达区间
25-261aa
-
氨基酸序列
MGSSHHHHHHSSGLVPRGSHMGSIVGGWECEKHSQPWQVAVYSHGWAHCG GVLVHPQWVLTAAHCLKKNSQVWLGRHNLFEPEDTGQRVPVSHSFPHPLY NMSLLKHQSLRPDEDSSHDLMLLRLSEPAKITDVVKVLGLPTQEPALGTT CYASGWGSIEPEEFLRPRSLQCVSLHLLSNDMCARAYSEKVTEFMLCAGL WTGGKDTCGGDSGGPLVCNGVLQGITSWGPEPCALPEKPAVYTKVVHYRK WIKDTIAANP
-
分子量
29 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
KLK2 (Kallikrein-related peptidase 2) is a serine protease that belongs to the kallikrein family and is primarily expressed in the prostate, making it a crucial biomarker for prostate cancer diagnostics. Its elevation in serum levels is associated with the presence of prostate cancer, distinguishing it from other conditions and aiding in the assessment of disease progression. Research into KLK2 recombinant proteins aims to better understand its structure, function, and interactions within the context of cancer biology. Additionally, KLK2 serves as a potential target for therapeutic interventions and vaccine development, paving the way for innovative treatments in prostate cancer management. The use of recombinant technology allows for the production of large quantities of KLK2 for further study, including experimental assays that elucidate its enzymatic properties and role in tumorigenesis. By studying KLK2 in detail, researchers hope to uncover insights that could lead to improved diagnostic tools and novel therapeutic strategies, ultimately enhancing patient care in prostate cancer treatment.
